Normosang (Human Hemin)

Human hemin, the active ingredient in Normosang, is a heme derivative presented as an intravenous solution for intravenous use. It is employed to treat acute intermittent porphyria and other acute hepatic porphyrias by addressing the underlying metabolic disturbance in affected patients. The preparation is administered under medical supervision in hospital settings and is indicated for rapid control of porphyric attacks, providing a sterile, preservative‑free formulation.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide.

Normosang acts on the heme biosynthetic pathway to treat acute porphyric disorders.

Acute intermittent porphyria: reduces severity and duration of acute attacks. Other acute hepatic porphyrias (e.g., variegate, hereditary coproporphyria): alleviates neurovisceral symptoms and prevents progression. Acute porphyria attacks: restores hepatic heme pool and suppresses toxic precursor accumulation.

Normosang may cause a range of adverse reactions following intravenous administration.

Common Side Effects: - Infusion site pain or phlebitis - Nausea or vomiting - Headache - Fever or chills - Mild hypotension - Transient elevation of liver enzymes

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reactions - Hemolysis, particularly in G6PD‑deficient patients - Acute renal impairment or failure - Severe hypotension requiring intervention - Thrombocytopenia or bleeding disorders - Hepatic dysfunction with marked enzyme elevation

When using Normosang, clinicians should observe specific safety measures.

Dose adjustment in renal impairment: monitor renal function and adjust infusion as needed. Avoid in patients with known hypersensitivity to hemin or formulation excipients. Use with caution in G6PD deficiency: increased risk of hemolysis. Monitor for signs of infection: maintain aseptic technique throughout preparation and administration. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human hemin can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent use with strong oxidizing agents: may increase hemolysis risk. - Co‑administration with other heme‑containing products: risk of cumulative overdose. - Use with drugs that induce ALA synthase (e.g., barbiturates, sulfonamides): may reduce therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor coagulation parameters for bleeding risk. - CYP450 substrates: observe for altered metabolism of co‑administered drugs. - Vitamin D analogues: monitor calcium and phosphate levels during therapy.